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Abstract
The epidemiology and microbiological characteristics of paediatric parapneumonic empyema (PPE) before the introduction of the new
generation of conjugate pneumococcal vaccines (10-valent and 13-valent) are described. All patients <14 years old admitted to a tertiary
paediatric hospital with a diagnosis of PPE were prospectively enrolled from January 2005 to December 2009. Pneumococcal serotyping
of culture-negative pleural fluid samples was performed using a multiplex real-time PCR assay. Overall, 219 patients had PPE. Incidence
rates for PPE remained stable during the study period with a not significant increase in 2009 compared with 2005 (p 0.13), and were
temporally associated with higher circulation of pandemic influenza A H1N1 during the last quarter in our population (p 0.001). Pneu-
mococci were detected in 72% of culture-positive and 79% of culture-negative samples. Serotypes were determined in 104 PPE cases.
Serotype 1 was the most prevalent serotype identified (42%) followed by serotypes 7F (20%), 3 (16%), 19A (8%) and 5 (7%). Serotype
distribution remained similar during all time periods. Pneumococcal serotype 1 remained the most common cause of PPE during the 5-
year study. The new generation of pneumococcal conjugate vaccines offers potential serotype coverage of 73% (10-valent) and 99% (13-
valent) in the population studied suffering from PPE. Continuous epidemiological and molecular studies are paramount to monitor the
impact of pneumococcal vaccines on the epidemiology of PPE.
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Introduction
Pleural parapneumonic empyema (PPE) often requires surgi-
cal intervention; it is associated with prolonged hospitaliza-
tion and a risk of long-term morbidity [1]. Since 2000 an
increase in the incidence of PPE has been observed in our
population as well as in other countries with Streptococcus
pneumoniae being the most commonly isolated micro-organ-
ism [2–5]. The reasons for this epidemiological change are
not clearly understood, partly because of the low sensitivity
in the diagnosis of this pathology using conventional microbi-
ological culture techniques.
In a transverse multicentre study we previously analysed
the epidemiology of PPE in Spain using multiple molecular
techniques [5]. Pneumococcal infection was proven in 79% of
cases with positive microbiological culture and in 84% of
pleural fluid samples; out of which nearly 90% were caused
by serotypes not included in the conjugated heptavalent
pneumococcal vaccine. Serotype 1 was responsible for pneu-
mococcal PPE in nearly 50% and similar observations have
been reported in other European countries as well as in cer-
tain areas of the USA [2,4]. The introduction of serotype 1
clone ST306, first detected in Spain in 1998, and its rapid
expansion from 2000, correlated with an increment of PPE
incidence [5,6]. The highly invasive pneumococcal serotype 1
is able to produce epidemic waves of variable duration and
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magnitude, which can markedly influence the epidemiology of
PPE on a geographic and temporal level [7–9].
The new generation of conjugated pneumococcal vaccines
(10-valent and 13-valent) has an optimized formulation that
theoretically covers the serotypes responsible for PPE during
the last years (serotypes included in the seven-valent vaccine:
4, 6B, 9V, 14, 18C, 19F and 23F; additional serotypes are 1,
5 and 7F in the 10-valent plus 3, 6A and 19A in the 13-valent
vaccine) [10]. The objective of this study was to describe the
epidemiology and microbiological characteristics of PPE in
the last years before the introduction of the new generation
of conjugated pneumococcal vaccines. Furthermore, we
investigated whether there have been changes in the distri-
bution of pneumococcal serotypes causing PPE, in particular
serotype 1, to improve the understanding of the current epi-
demic wave. Finally, the influence of the pandemic influenza
H1N1 on PPE was described.
Patients and Methods
Setting and study population
All patients <14 years old admitted to Hospital Universitario
Infantil Virgen del Rocio (HUIVR) in Sevilla with a diagnosis of
PPE were prospectively enrolled from January 2005 through
to December 2009. This is a tertiary paediatric hospital that
served a referral population of 463 070 children in 2009.
Ascertainment and management of PPE cases
PPE was defined according to published criteria [2]. Require-
ments for thoracocentesis, thoracoscopy and antimicrobial
therapy were determined according to usual clinical practice
and to the discretion of the attending physician. Patients with
PPE not requiring thoracocentesis or surgical decortication
were excluded, as were cases with pleural fluid analysis con-
sistent with a transudate. Thoracocentesis was performed by
paediatric surgeons, except for acutely ill patients who were
urgently tapped in the emergency department or the inten-
sive care unit. Written informed consent was obtained from
the parent or legal guardian of participating children before
thoracocentesis. Pleural fluid specimens were sent for rou-
tine microbiological culture and biochemical analysis; the
remaining fluid was frozen at )80C for further molecular
testing. Clinical, demographic and outcome data were
collected using a standardized case-report form.
Microbiological analysis
The PPE was defined according to conventional microbiologi-
cal culture results as (i) culture-positive cases with organism
identified from blood, pleural fluid or gastric washing (for
Mycobacterium tuberculosis only), and (ii) culture-negative
cases when no organisms could be isolated in any of those
samples. Pneumococcal isolates from culture-positive cases
were further serotyped using the Quellung method, per-
formed by the Pneumococcal Reference Laboratory (Majada-
honda). Pneumococcal identification and serotyping of
culture-negative cases were performed retrospectively using
PCR methodology as previously described [5,11]. Briefly, cul-
ture-negative pleural fluid specimens were analysed using a
pneumolysin gene PCR assay and a confirmatory real-time
PCR assay for the detection of the S. pneumoniae wzg gene.
Determination of pneumococcal serotypes was performed
using ten groups of real-time PCR typing assays covering 24
serotypes (1, 3, 4, 5, 6A, 6B, 7F/A, 8, 9V/A/N/L, 14, 15B/C,
18C/B, 19A, 19F/B/C, 23F and 23A). In the last quarter of
2009 co-infection with pandemic influenza A virus (H1N1)
was investigated using primers and conditions used by the
Centers for Disease Control (Atlanta, GA) [12]. Current
Clinical and Laboratory Standards Institute (CLSI, Wayne,
PA) breakpoints [13] were considered for non-susceptibility
(intermediate plus resistance) interpretation: parenteral peni-
cillin (‡4 g/mL) and, erythromycin (‡0.5 g/mL).
Statistical analysis
Statistical analysis was performed using SPSS for Windows
(version 17.0). Descriptive analyses were performed using
medians, interquartile ranges (IQR), frequency distributions
and percentages. Incidence rates of PPE were calculated for
each year using the frequency of Accident and Emergency
patients, identified from an administrative database, as
denominator. Z-test was used to compare these rates at the
95% confidence level. Comparison of frequency of PPE cases
during the last quarter in 2009 with the historical average
was performed using one sample Student’s t-test. Analysis of
categorical variables was carried out using the chi-square test
and the Fisher’s exact test, as appropriate. All p-values were
two-tailed, and the level of significance was set at 0.05.
Results
Demographic characteristics and outcome
From 2005 to 2009 a total of 219 children diagnosed with
PPE were admitted. Median age and duration of clinical
symptoms before admission were 44 months (IQR 32–70)
and 4 days (IQR 3–6), respectively. All but 22 (10%) of the
children received antibiotic therapy before thoracocentesis.
Approximately one-third of the patients (35%) were referred
from other hospitals. Information regarding PCV7 vaccination
status was available in 197 children (90%); of which 91 (46%)
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had received at least one dose. Video-assisted thoracoscopy
was performed in 138/219 patients (63%) of whom 25 (18%)
were secondary after clinical failure of thoracocentesis and
chest tube insertion. Median length of hospitalization was
9 days (IQR 6–13); 66 patients (30%) required management
in the Intensive Care unit. There were no fatalities.
Frequency of disease
The incidence of PPE in 2005 was 60/100 000 children
attending the paediatric Accident + Emergency department;
this was followed by a non-significant decline of cases during
2006 and 2007. Incidence then increased steadily to a total
of 82/100 000 in 2009 (p 0.13 compared with 2005) as seen
in Fig. 1. The frequency of PPE cases was significantly higher
in the last quarter of 2009 compared with the mean fre-
quency in 2005–2008 (29 versus 13.5, range 11–17; p 0.001)
with S. pneumoniae being the cause in 89% (Fig. 2). This
coincided with the highest prevalence of pandemic influenza
A (H1N1). An unusual cluster of six cases was observed in
September 2009, compared with a cumulative frequency of
one case in 2005–2008 during the same month.
Microbiological analysis and distribution of pneumococcal
serotypes
A micro-organism in blood and pleural fluid culture was
identified in 47/219 (21%) children out of whom S. pneumo-
niae was isolated in 34 (72%) patients (Table 1). Other
organisms included Streptococcus pyogenes and M. tuberculosis
(n = 4 each), Staphylococcus aureus (n = 3) and Haemophilus
influenzae non-typable (n = 2). In patients with a negative
culture result additional PCR for S. pneumoniae from pleural
fluid was performed in 118/172 (69%) and the results were
positive in 93/118 (79%). All pneumococcal culture isolates
were sensitive to penicillin. Parenteral penicillin and
erythromycin non-susceptibility rates were 0% and 3%,
respectively.
From 127 children diagnosed with S. pneumoniae PPE (34
using culture and 93 using molecular PCR methodology), 104
samples were successfully serotyped. A total of ten pneumo-
coccal serotypes were identified; serotype 1 was isolated in
39 (42%) patients, followed by serotypes 7F (n = 21), 3
(n = 17), 19A (n = 8), 5 (n = 7) and 14 (n = 3); serotypes
9V, 19F, 12A and 6A were isolated from one patient each
and this is summarized in Table 2. All the PCV7 strains were
isolated from non-immunized patients. There was no
significant difference regarding the distribution of those sero-
types between January 2005 to June 2007 and July 2007 to
December 2009.
Co-infection with pandemic influenza A virus (H1N1)
During the last quarter of 2009, 22/29 patients diagnosed with
PPE were also tested for co-infection with pandemic influenza
A virus (H1N1) using real-time PCR, 8/22 children were
found to be co-infected. In these eight patients S. pneumoniae
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FIG. 1. Annual incidence of parapneumonic empyema at the HUIVR
Sevilla from 2005 to 2009.
TABLE 1. Microbiological characteristics of all children
(n = 219) with parapneumonic empyema
Number of
patients (%)
Culture
positive (n = 47)
PCR
positive (n = 118)
Streptococcus pneumoniae 34 (72) 93 (79)
Streptococcus pyogenes 4 (9) NA
Mycobacterium tuberculosis 4 (9) NA
Staphylococcus aureus 3 (6) NA
Haemophilus influenzae non-typable 2 (4) NA
NA, not applicable.
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FIG. 2.Quarterly frequencies of parapneumonic empyema cases
between 2005 and 2009. *2009 versus 2005–2008, p 0.001.
CMI Obando et al. Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema 765
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 763–768
and methicillin-resistant Staphylococcus aureus (MRSA; USA300
clone) were isolated in six and one case, respectively.
Discussion
This study investigates the epidemiology of PPE in a tertiary
centre with high incidence of this pathology. The use of
molecular techniques in addition to conventional microbial
cultures resulted in an increased identification of pathogens
in this study group. In addition pneumococcal serotypes
causing PPE over the last 5 years were determined. These
data will provide useful baseline information for future stud-
ies of the effectiveness in PPE of the new generation of con-
jugated pneumococcal vaccines. After a continuous increase
of PPE from 1998 to 2005, incidence plateaued subsequently
and increased by 38% in 2009 compared with 2005; which
was probably related to the circulation of the pandemic influ-
enza A virus (H1N1) [5].
In this study, PCR from pleural fluid was only used to
detect S. pneumoniae. The incidence of potential pathogens
other than S. pneumoniae was not investigated in culture-neg-
ative pleural fluid. Even though some research has used
broad-range 16S rDNA or multiplex PCR to increase the
spectrum of micro-organisms causing PPE, its potential use in
our setting is limited because the vast majority of PPE are
the result of S. pneumoniae [14,15]. However, this might
change in the future, as has been the case in the USA, where
community-associated MRSA has become the commonest
pathogen causing PPE [16]. To date community-associated
MRSA is still an unusual finding in our population group but
close surveillance is important because of its epidemic and
virulent potential [17,18].
There was a temporal association between the pandemic
influenza A virus (H1N1) and PPE in our population group.
The frequency of children with PPE was, compared with pre-
vious years, significantly higher during the last quarter of
2009, correlating with the highest prevalence of H1N1 cases
[19]. An unusual cluster of children with PPE was admitted
to the hospital in September 2009 coinciding with increased
circulation of the H1N1 virus. During this month, PPE is usu-
ally very rare because viral infections are uncommon at this
time because school activities in southern Spain start in late
September. During the last quarter of 2009, 36% of children
with PPE had evidence of co-infection with influenza A virus
(H1N1). Similar observations were made in other geographic
areas, supporting our findings [20,21].
All pneumococcal isolates were susceptible to parenteral
penicillin. This finding coincides with the significant decrease
in penicillin non-susceptibility observed in Spain in recent
years, probably because of the introduction of PCV7 and a
reduction in antibiotic consumption [22]. In addition, highly
invasive serotypes tend to be over-represented in PPE cases
and these serotypes are not generally associated with antibi-
otic resistance.
Pneumococcal serotypes isolated from PPE in this study
are covered by conjugated heptavalent, and the new genera-
tion 10-valent and 13-valent pneumococcal vaccines in 5%,
73% and 99%, respectively. Throughout the study serotype 1
was persistently predominant and responsible for over 40%
of PPE. Therefore, serotype 1 being highly relevant in the
epidemiology of this disease must be considered as a priority
candidate for vaccine strategies. However, there are uncer-
tainties regarding the potential impact of the new generation
of conjugated vaccines and the current circulating epidemic
serotype 1. PPE caused by serotype 1 is more common in
older children compared with other serotypes; so short-
term vaccine effectiveness will depend mainly on herd immu-
nity. Colonization rates of serotype 1 and immunization rates
in our geographic area are generally low, so one might not
expect a significant impact on serotype 1 carriage circulation
[5,7]. In this respect only 11% of children with serotype 1
TABLE 2. Distribution of pneumococcal serotypes in children with parapneumonic empyema
Serotype
Number of patients (%)
January 2005 to June 2007 (n = 53) July 2007 to December 2009 (n = 51) Total (n = 104) p-valuea
1 23 (43) 21 (41) 44 (42) 0.82
7F 14 (26) 7 (14) 21 (20) 0.11
3 8 (15) 9 (18) 17 (16) 0.72
19A 2 (4) 6 (12) 8 (8) 0.16
5 2 (4) 5 (10) 7 (7) 0.27
14 2 (4) 1 (2) 3 (3) 1
9V 0 1 (2) 1 (1) 1
19F 1 (2) 0 1 (1) 1
12A 0 1 (2) 1 (1) 1
6A 1 (2) 0 1 (1) 1
aFor comparison of time periods: 1 January 2005 to 31 June 2007 versus 1 July 2007 to 31 December 2009.
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infection in this study were aged <2 years (vaccine target
population in routine vaccine schedule without catch-up)
whereas 52% were >5 years. In addition, independent of vac-
cine pressure, temporal fluctuations of serotype 1 prevalence
can result in a marked decline because of its own clonal
dynamics, as was recently the case in Utah [15]. To further
understand the above and the impact of vaccines on the glo-
bal incidence of PPE as well as the distribution of pneumo-
coccal serotypes, we will continue to survey the
epidemiology of PPE using molecular technology.
There are several limitations to this study. First, data were
collected from a single centre and results may differ in other
geographic locations. However, the epidemiology of PPE has
been consistent over the last years in our country with no
differences in the relevance of pneumococcal disease and the
distribution of pneumococcal serotypes [5,23,24]. Second,
seasonal changes in climatic parameters and, apart from the
pandemic influenza A, virus circulation were not studied; fac-
tors that have been shown to influence the incidence of
pneumococcal PPE [25,26]. Third, molecular serotyping in
our study was limited to the detection of 24 serotypes;
therefore it cannot be ruled out that some unusual sero-
types not included in the screening caused PPE have not
been detected [11]. Finally, the distribution of pneumococcal
serotypes in uncomplicated pneumonia was not investigated
and might have been different [2].
In conclusion, pneumococcal serotype 1 was mainly and
persistently responsible for the high incidence of PPE since
2005 in our centre. Theoretically the new generation of con-
jugate pneumococcal vaccine (10-valent and 13-valent) offers
high protection against the serotypes isolated from children
with PPE during the study period. Prevalence of PPE was sig-
nificantly influenced by the pandemic influenza A (H1N1)
virus. Ongoing epidemiology surveillance using molecular
techniques is necessary to understand the influence of these
vaccines on the epidemiology of PPE in the future.
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